Elekta AB (publ) (OTCMKTS:EKTAY) Issues Earnings Results, Misses Estimates By $0.01 EPS

Elekta AB (publ) (OTCMKTS:EKTAY) released its quarterly earnings results on Friday. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01), Zacks reports. Elekta AB (publ) had a net margin of 5.65% and a return on equity of 11.07%. The firm had revenue of $416.86 million for the quarter, compared to analysts’ expectations of $435.89 million.

Elekta AB (publ) Stock Down 8.0 %

Shares of OTCMKTS EKTAY opened at $5.60 on Friday. The company has a current ratio of 1.05, a quick ratio of 0.81 and a debt-to-equity ratio of 0.60. Elekta AB has a 12-month low of $5.25 and a 12-month high of $8.24. The firm’s 50-day moving average price is $5.71 and its 200-day moving average price is $6.09. The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of 22.40 and a beta of 1.22.

Elekta AB (publ) Cuts Dividend

The firm also recently announced a dividend, which will be paid on Thursday, March 27th. Stockholders of record on Friday, March 7th will be issued a $0.1072 dividend. The ex-dividend date is Friday, March 7th. Elekta AB (publ)’s dividend payout ratio (DPR) is presently 48.00%.

Analyst Upgrades and Downgrades

Separately, Sanford C. Bernstein upgraded Elekta AB (publ) from a “strong sell” rating to a “hold” rating in a research report on Wednesday, January 29th.

About Elekta AB (publ)

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.